Washington University School of Medicine

Digital Commons@Becker
2020-Current year OA Pubs

Open Access Publications

1-1-2022

Prognostic value of serum neurofilament light chain for disease
activity and worsening in patients with relapsing multiple
sclerosis: Results from the phase 3 ASCLEPIOS I and II trials
Tjalf Ziemssen
University Clinic Carl-Gustav Carus

Anne H Cross
Washington University School of Medicine in St. Louis

et al.

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4
Part of the Medicine and Health Sciences Commons

Recommended Citation
Ziemssen, Tjalf; Cross, Anne H; and et al., "Prognostic value of serum neurofilament light chain for
disease activity and worsening in patients with relapsing multiple sclerosis: Results from the phase 3
ASCLEPIOS I and II trials." Frontiers in Immunology. 13, 852563 (2022).
https://digitalcommons.wustl.edu/oa_4/650

This Open Access Publication is brought to you for free and open access by the Open Access Publications at
Digital Commons@Becker. It has been accepted for inclusion in 2020-Current year OA Pubs by an authorized
administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

ORIGINAL RESEARCH
published: 31 March 2022
doi: 10.3389/fimmu.2022.852563

Prognostic Value of Serum
Neuroﬁlament Light Chain for
Disease Activity and Worsening in
Patients With Relapsing Multiple
Sclerosis: Results From the Phase 3
ASCLEPIOS I and II Trials
Edited by:
Angel Perez Sempere,
Hospital General Universitario de
Alicante, Spain
Reviewed by:
Omid Mirmosayyeb,
Isfahan University of Medical Sciences,
Iran
Gabriel Bsteh,
Medical University of Vienna, Austria
*Correspondence:
Tjalf Ziemssen
Tjalf.Ziemssen@uniklinikum-dresden.de
Specialty section:
This article was submitted to
Multiple Sclerosis
and Neuroimmunology,
a section of the journal
Frontiers in Immunology
Received: 11 January 2022
Accepted: 07 March 2022
Published: 31 March 2022
Citation:
Ziemssen T, Arnold DL, Alvarez E,
Cross AH, Willi R, Li B, Kukkaro P,
Kropshofer H, Ramanathan K,
Merschhemke M, Kieseier B, Su W,
Häring DA, Hauser SL, Kappos L and
Kuhle J (2022) Prognostic Value of
Serum Neuroﬁlament Light Chain for
Disease Activity and Worsening in
Patients With Relapsing Multiple
Sclerosis: Results From the Phase 3
ASCLEPIOS I and II Trials.
Front. Immunol. 13:852563.
doi: 10.3389/fimmu.2022.852563

Tjalf Ziemssen 1*, Douglas L. Arnold 2,3, Enrique Alvarez 4, Anne H. Cross 5, Roman Willi 6,
Bingbing Li 7, Petra Kukkaro 6, Harald Kropshofer 6, Krishnan Ramanathan 6,
Martin Merschhemke 6, Bernd Kieseier 6, Wendy Su 7, Dieter A. Häring 6,
Stephen L. Hauser 8, Ludwig Kappos 9,10 and Jens Kuhle 9,10
1 Center of Clinical Neuroscience, Department of Neurology, University Clinic Carl-Gustav Carus, Dresden, Germany, 2 Brain
Imaging Centre, Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada, 3 NeuroRx Research,
Montreal, QC, Canada, 4 Department of Neurology, Rocky Mountain MS Center at the University of Colorado, Aurora,
CO, United States, 5 Department of Neurology, Washington University School of Medicine, Saint Louis, MO, United States,
6 Novartis Pharma AG, Basel, Switzerland, 7 Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States,
8 UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco,
CA, United States, 9 Neurologic Clinic and Policlinic and MS Center, Department of Head, Spine and Neuromedicine,
University Hospital Basel, Basel, Switzerland, 10 Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB),
Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland

Objective: This study aims to conﬁrm the prognostic value of baseline serum
neuroﬁlament light chain (sNfL) for on-study disease activity and worsening in patients
with relapsing MS (RMS).
Background: Previous post-hoc studies suggested that sNfL could be a prognostic
biomarker in RMS. In the phase 3 ASCLEPIOS I/II trials in which ofatumumab
demonstrated better efﬁcacy outcomes than teriﬂunomide, treatment with ofatumumab
also led to signiﬁcantly reduced sNfL levels compared to teriﬂunomide treatment.
Design/Methods: In this study, we report protocol-planned analyses from the pooled
ASCLEPIOS I/II trials (N=1882). Per protocol, patients were stratiﬁed by median baseline
sNfL levels (9.3 pg/ml) into high (>median) and low (≤median) categories to prognosticate:
annualized rate of new/enlarging T2 (neT2) lesions in year 1 and 2, annualized relapse rate,
annual percentage change in whole brain (WB) and regional brain volume [thalamus, white
matter (WM), cortical gray matter (cGM)], and disability outcomes. Similar analyses were
performed for the recently diagnosed (within 3 years), treatment-naive patients (no prior
disease-modifying therapy) subgroup.
Results: High versus low sNfL at baseline was prognostic of increased on-study T2 lesion
formation at year 1 (relative increase: ofatumumab +158%; teriﬂunomide +69%, both
p<0.001), which persisted in year 2 (+65%, p=0.124; +46%, p=0.003); of higher annual
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percentage change of WB volume (ofatumumab, −0.32% vs. −0.24%, p=0.044, and
teriﬂunomide, −0.43% vs. −0.29%, p=0.002), thalamic volume (−0.56% vs. −0.31%,
p=0.047 and −0.94% vs. −0.49%, p<0.001), and WM volume (−0.30% vs. −0.19%,
p=0.083 and −0.38% vs. −0.18%, p=0.003) but not of cGM volume (−0.39% vs. −0.32%,
p=0.337 and −0.49% vs. −0.46%, p=0.563). A single sNfL assessment at baseline was
not prognostic for on-study relapses or disability worsening. Results were similar in the
subgroup of recently diagnosed, treatment-naive patients.
Conclusion: This study conﬁrms that baseline sNfL levels are prognostic of future onstudy lesion formation and whole brain and regional atrophy in all RMS patients, including
recently diagnosed, treatment-naive patients.
Keywords: serum neuroﬁlament light chain, prognostic biomarker, MS disease activity, lesion formation,
brain atrophy

neuro-axonal injury released into the cerebrospinal ﬂuid (CSF)
and serum following neuro-axonal damage (16, 17). Serum and
CSF NfL concentrations are highly correlated (18–23), and levels
of serum NfL (sNfL) are higher in patients diagnosed with MS
compared with age-matched healthy controls (3, 20, 24). NfL has
been proposed as a prognostic and monitoring biomarker in MS
to assess disease activity; the cumulative evidence for NfL has
been reviewed elsewhere (25). In patients with RMS, high sNfL
levels were found to correlate with active T2 lesions and relapses
(3, 16, 20) and brain volume loss (26), suggesting that measuring
sNfL levels can add value as a prognostic biomarker to identify
patients at higher risk for future disease activity that can assist
clinicians in decision-making (3, 18, 24, 27, 28).
There is currently an unmet need for a highly standardized,
minimally invasive biomarker test, such as sNfL, to stratify
diagnosed RMS patients into high- and low-risk groups based
on the risk and intensity of anticipated future MS disease activity.
The unmet need of prognosticating the risk of future MS disease
activity is pronounced in newly diagnosed RMS patients who have
not yet received a disease-modifying therapy (DMT) and in
patients who discontinued from their prior treatment and aim
to switch to another therapy. Several DMTs, including B-celldepleting therapies, have shown an effect on lowering sNfL levels
compared with untreated patients, independent of other variables
(16, 29, 30). Initiating or switching to highly effective DMTs can
decrease sNfL levels (3, 7, 16, 22) and improve long-term clinical
outcomes for patients with RMS (31). Ofatumumab, a fully human
anti-CD20 monoclonal antibody, selectively depletes B cells at a
monthly dosing of 20 mg administered subcutaneously (30). In the
phase 3 ASCLEPIOS I and II trials, ofatumumab signiﬁcantly
lowered sNfL levels at the ﬁrst assessment at month 3 and at all
subsequent visits compared with oral teriﬂunomide (14 mg daily)
in patients with RMS (30).
The present analysis aims to test and conﬁrm the prognostic
value of baseline sNfL for clinical and sub-clinical disease activity
and disability outcomes based on a pre-planned analysis in two
large, well-controlled phase 3 trials (ASCLEPIOS I/II) in RMS.
We hypothesized that patients with a “high” (>median) versus
“low” (≤median) sNfL value at baseline would have higher

1 INTRODUCTION
Multiple sclerosis (MS) is a chronic, immune-mediated disease of
the central nervous system (CNS), characterized by inﬂammation,
demyelination, brain tissue, and neuronal loss, ultimately leading
to severe disability (1). The hallmark of relapsing MS (RMS) are
recurrent episodes of inﬂammatory demyelination in the brain
and spinal cord, which can be accompanied by acute neurological
symptoms (“MS relapse”), by nonspeciﬁc symptoms (e.g., pain or
fatigue), or remain asymptomatic (i.e., subclinical MS lesion
activity). The vast majority (~90%) of the focal inﬂammatory
lesions in RMS, as measured on brain magnetic resonance imaging
(MRI), are not associated with overt neurological symptoms but
occur as subclinical lesion activity (2). However, despite most MRI
lesions not being associated with acute neurological symptoms,
lesion activities contribute to putatively irreversible changes such
as neuronal damage and loss (3) and brain and spinal cord atrophy
(4). MS-related changes in brain (5), thalamic (6, 7) and spinal
cord volume (8), and neuronal injury/loss (9–11) have been shown
to be associated with poor long-term outcomes in MS.
MS treatment guidelines recommend consideration of
patients’ level of disease activity and severity when making the
initial and subsequent treatment decisions (12, 13). However,
there is currently no accepted consensus deﬁnition that allows
physicians to classify RMS patients into either “high-risk” or
“low-risk” groups in order to prioritize treatment strategies (12).
A great challenge encountered in clinical practice concerning
RMS patients is the difﬁculty in prognosticating the risk of future
MS disease activity because of the extreme variability of MS
disease course between patients (14) and the absence of
prognostic tools. In current clinical practice, disease activity
and severity are assessed mainly on the basis of the patient’s
disease history and through evaluation of MRI, which are
imperfect surrogates (15).
Biomarkers that can help to more reliably prognosticate
future disease activity based on a standardized test could
complement clinical and radiological assessments and would
be of high value for decision making in routine clinical practice
(3). Neuroﬁlament light chain (NfL) is a speciﬁc biomarker of
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the assay were veriﬁed by testing two QC samples, prepared at a
nominal concentration of 2.05 and 1,900 pg/ml, in 60
measurements each, in duplicate. The LLoQ and ULoQ were
deﬁned as the means of the 60 measurements, with total
precision (%CV) within the predeﬁned acceptance criteria
(≤25% at LLoQ, ≤20% at ULoQ). The LLoQ and ULoQ were
veriﬁed at 2.8 and 1,546 pg/ml, establishing the reportable range.
Intra-assay precision was demonstrated by testing eight samples
in duplicate, across the assay reportable range independently six
times in a single run, with the highest observed coefﬁcient of
variation (CV) of 10%. Interassay precision was demonstrated by
testing eight samples in duplicate, independently three times per
run for six runs (two runs per day), with the highest observed CV
of 11%.

number of demyelinating events as measured by new or
enlarging T2 (neT2) lesions or clinical relapses and more brain
volume loss.

2 METHODS
2.1 Trial Design and Patients
This is a protocol-planned analysis from the pooled ASCLEPIOS
I (NCT02792218) and ASCLEPIOS II (NCT02792231) trials (30)
in patients with RMS who were randomly assigned (1:1) to
receive either subcutaneous ofatumumab 20 mg every 4 weeks
(starting at week 4, after initial doses of 20 mg on days 1, 7, and
14) or oral teriﬂunomide 14 mg once daily, for up to 30 months.
Brieﬂy, ASCLEPIOS I and II were randomized, double-blind,
double-dummy, active-controlled, multicenter trials of identical
design conducted concurrently in patients with RMS. Patients
aged 18–55 years; a diagnosis of relapsing MS (either relapsing–
remitting MS or secondary progressive MS with disease activity);
an Expanded Disability Status Scale (EDSS) score of 0–5.5
(inclusive); at least one relapse in the year before screening or
at least two relapses in the 2 years before screening or at least one
gadolinium-enhancing (Gd+) lesion on MRI in the year before
randomization; and a neurologically stable condition for at least
a month before randomization were included in the study (30).
Protocol-required washout periods for patients who transitioned
off another DMT (i.e., treatment switchers) are detailed in
Hauser et al. (30). The protocols were approved by the relevant
institutional review board or ethics committee at each trial site,
and all patients provided written informed consent.

2.3 Study Outcomes and Assessments
All study objective, outcomes, and assessments were
prospectively deﬁned in the study protocols of ASCLEPIOS I
and II. Baseline sNfL concentration was assessed prior to ﬁrst
dose of study treatment (ofatumumab or teriﬂunomide). MRI
scans were performed at baseline, at months 12 and 24, and endof-treatment/end-of-study (EOT/EOS, if no other scan was
available within 3 months).
The prognostic value of baseline sNfL for on-study disease
activity and worsening was analyzed for the annualized rate of
neT2 lesion formation, annualized relapse rate (ARR), and
annualized rate of percentage whole brain volume change and
percentage volume change in regional brain compartments:
thalamic volume, hemispheric white matter (WM), and cortical
gray matter (cGM). To investigate the prognostic value of sNfL
on future disease activity and worsening in patients who
appeared “free of disease activity” at baseline based on the
radiological assessment, similar analyses of lesion formation
and brain volume loss were performed in the subset of patients
without Gd+ T1 lesions at baseline. The time to ﬁrst 3- and 6month conﬁrmed disability worsening (3m/6mCDW) were
summarized descriptively, as the studies were not powered for
this assessment, as acknowledged in the study protocols. To
assess the clinical utility of sNfL as a prognostic tool in early RMS
patients, similar analyses were performed in the protocol-deﬁned
subgroup of patients who were recently diagnosed (i.e., had the
diagnosis of MS within 3 years) and who were treatment naive at
baseline (i.e., had not received a prior MS treatment).

2.2 NfL Assay and
Performance Characteristics
Quantitation of NfL in human serum was performed centrally at
one site, Navigate BioPharma Services, Carlsbad, CA, using the
Quanterix Simoa NF-light assay advantage kit, which is a twostep quantitative digital immunoassay. Samples were collected
from patients between the start and end of the study, i.e., between
August 2016 and July 2019. Samples were analyzed in a single
batch at the end of the study; maximal storage time was <3 years.
For pre-processing of samples, approximately 3.5ml of blood was
collected to serum separator tubes. Samples were inverted for a
minimum of ﬁve times, and samples were allowed to clot 30–60
min at room temperature before centrifugation with a swing
bucket for 10 min at 1,100 to 1,500 G-force or 15 min in a ﬁxed
angle centrifuge. Serum was aliquoted to pre-chilled cryovials
and frozen at −70°C. Samples were shipped on dry ice and stored
at a central laboratory until further testing.
Prior to the analysis of study samples, a technical assessment
was performed to validate the performance claims of the
Quanterix Simoa NfL kit in a serum matrix for use as a clinical
trial assay. Lower limit of blank, lower limit of detection, and
lower limit of quantiﬁcation (LLoQ) were ﬁrst established
according to Clinical and Laboratory Standards Institute
(CLSI) guideline (0.406, 2.05, and 2.05 pg/ml, respectively)
(32). The LLoQ and upper limit of quantiﬁcation (ULoQ) for
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2.4 Statistical Methods
The statistical methodology, including NfL thresholds and
subgroup deﬁnitions, was predeﬁned in the statistical analysis
plan of ASCLEPIOS I and II in year 2016, before any study data
were collected. The pooled ASCLEPIOS I and II trial data were
carried out on the full analysis set that comprised all randomized
patients with assigned treatments. The baseline sNfL cutoff was
predeﬁned by the median NfL value across both studies to
stratify a typical RMS population (as per the inclusion and
exclusion criteria of the ASCLEPIOS I and II trials) into “high”
and “low” sNfL groups of similar sample size before collecting
any data. After completion of the phase 3 studies, the median
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computed. Disability worsening was described based on a Cox
regression model adjusted for study as stratum, treatment, region,
and baseline sNfL category as factors and baseline EDSS score as a
continuous covariate along with treatment-by-baseline sNfL
category interaction. The statistical hypothesis test of the
prognostic value of sNfL for disability changes was based on the
main effect of sNfL category (due to the expected low number of
events in this subgroup). It is acknowledged that the study was not
powered to show an effect on disability outcomes in subgroups.

baseline sNfL level was determined as 9.3 pg/ml in the statistical
analysis, and patients were stratiﬁed accordingly into high (>9.3
pg/ml) and low (≤9.3 pg/ml) sNfL categories. The prognostic
effect of baseline sNfL on MS disease activity (i.e., inﬂammatory
demyelinating events) was performed based on MRI lesions or
clinical relapses. The annualized rate of neT2 lesions was
analyzed using a negative binomial regression model adjusted
for treatment, baseline sNfL category, region, and study as
factors; age and baseline volume of T2 lesions as continuous
covariates; and treatment by baseline sNfL category interaction
and the natural log of the time from the baseline scan (in years)
as an offset. ARR was analyzed using a negative binomial
regression model with log-link to the number of relapses,
adjusted for treatment, baseline sNfL category, region, and
study as factors; number of relapses in the previous year,
baseline EDSS score, baseline number of Gd+ T1 lesions, and
patient’s age at baseline as covariates; and treatment by baseline
NfL category interaction and the natural log of the time-in-study
as an offset.
The prognostic effect of baseline sNfL on MS disease worsening
was assessed based on brain volume change and a descriptive
analysis of disability worsening. The annual rate of both whole and
regional brain volume percent changes was analyzed using the
random coefﬁcients model adjusted for study, treatment, region,
and baseline sNfL category as ﬁxed effects factors; time, baseline
number of Gd+ T1 lesions, baseline T2 volume, and normalized
brain volume (whole or regional) at baseline as continuous
covariates; and treatment-by-time-by-baseline sNfL category
interaction and the three corresponding two-way interactions.
Random terms for slopes and the intercept were also included.
The annual rate of brain volume loss was estimated based on the
slope from a random coefﬁcient model in the post-baseline
assessments, i.e., the slope is estimated between year 1 and 2.
Pearson correlation coefﬁcients between baseline sNfL and
regional brain volume changes at months 12 and 24 were

3 RESULTS
3.1 Patients
Of the 1,882 patients in the ASCLEPIOS I and II trials, 1,746
(92.8%) patients had serum NfL samples available at baseline. Of
these, 870 (49.8%) were categorized as “high” and 876 (50.2%) as
“low” baseline sNfL group. The baseline demographic and
disease characteristics of patients by “high” and “low” sNfL are
summarized in Table 1. The mean age, disease duration, and
number of relapses in the previous year before the study were
similar between the groups. The median baseline sNfL level was
6.76 pg/ml in the low and 14.23 pg/ml in the high sNfL
categories. Patients with high sNfL levels differed from those
with low sNfL levels by having a higher baseline T2 lesion
volume (16.7 vs. 9.4 cm3), higher mean number of Gd+ T1
lesions (2.6 vs. 0.4), and a lower probability of being free of Gd+
T1 lesions (44% vs. 78%). Of the 870 high sNfL patients, 455
(52.3%) were randomly allocated to ofatumumab and 415
(47.7%) to teriﬂunomide; and of the 876 low sNfL patients,
438 (50.0%) were randomly allocated to ofatumumab and 438
(50.0%) to teriﬂunomide.
The baseline characteristics of the subgroup of recently
diagnosed treatment-naive patients (n=576) are presented in
(Table 1). Recently diagnosed, treatment-naive patients had a

TABLE 1 | Demographics and baseline characteristics in the overall study population, and in the subgroup of recently diagnosed, treatment-naive patients, by sNfL
baseline high–low.
All patients
Parameters

Age (years)
Sex, female, n (%)
MS duration since ﬁrst symptom (years)
Previously treated with DMT
Number of relapses in the year before the study
Time since onset of most recent relapse (months)
EDSS score
Normalized brain volume (cm3)
Number of Gd+ T1 lesions
Patients free of Gd+ T1 lesions, n (%)
T2 lesion volume (cm3)
sNfL (pg/ml), median

Recently diagnosed, treatment-naive patients

Low sNfL category
(≤9.3 pg/ml)
N=876*

High sNfL category
(>9.3 pg/ml)
N=870*

Low sNfL category
(≤9.3 pg/ml)
N=274*

High sNfL category
(>9.3 pg/ml)
N=302*

38.6 ± 8.5
588 (67.1)
8.3 ± 7.3
560 (59.2)
1.2 ± 0.7
7.8 ± 13.5
2.8 ± 1.3
1447.6 ± 74.8
0.4 ± 1.2
679 (77.5)
9.4 ± 10.6
6.76

37.8 ± 9.7
602 (69.2)
7.9 ± 6.9
573 (61.2)
1.3 ± 0.7
7.0 ± 9.4
3.0 ± 1.4
1437.2 ± 81.0
2.6 ± 5.4
383 (44.0)
16.7 ± 15.1
14.23

36.7 ± 8.8
180 (65.7)
3.5 ± 4.4
–
1.3 ± 0.7
5.8 ± 4.8
2.2 ± 1.2
1478.4 ± 64.9
0.4 ± 1.0
206 (75)
5.9 ± 7.2
6.77

35.9 ± 9.7
209 (69.2)
3.1 ± 3.6
–
1.3 ± 0.7
5.8 ± 5.7
2.3 ± 1.2
1468.2 ± 71.1
2.6 ± 4.8
116 (38)
12.3 ± 12.4
15.29

The baseline sNfL level used for high–low stratiﬁcation was assessed prior to ﬁrst study treatment. Data are expressed as mean ± SD unless speciﬁed otherwise.
*Only patients with non-missing baseline NfL values are included.
EDSS, expanded disability status scale; Gd+, gadolinium-enhancing; SD, standard deviation; sNfL, serum neuroﬁlament light chain.
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The difference in brain volume between patients with a high
(vs. low) baseline NfL level was most pronounced in the
thalamus (relative difference: ofatumumab, 76.5%, p=0.047;
teriﬂunomide, 91.5%, p<0.001) (Figure 2B) and also was
prognostic of a higher annual volume change between year 1
and 2 in hemispheric WM (59.3%, p=0.083; 109.7%, p=0.003)
(Figure 2C) but not of cGM volume change (19.7%, p=0.337;
8.7%, p=0.563) (Figure 2D). Baseline sNfL correlated
signiﬁcantly with the percentage change from baseline to
month 12 in whole brain volume (ofatumumab r=−0.200;
teriﬂunomide r=−0.203, both p<0.0001), thalamic volume
change (−0.374; −0.308, both p<0.0001), and WM (−0.230;
−0.207, both p<0.0001) but less so with cGM volume change
(−0.026, p=0.4679; −0.070, p=0.0523). Similar results were
observed for the percentage change from baseline to month 24.
The strongest correlation of sNfL change was with thalamic
volume loss, both over 1 and 2 years (Table 2; Figures 3A, B).
The difference in the risk of 3mCDW (Figure 2E) or 6mCDW
(Figure 2F) was not statistically signiﬁcant between high and low
sNfL groups, but trended in the expected direction, consistent
with the change in brain volume.

shorter disease duration, were less disabled, and had a higher
brain volume and a lower T2 lesion volume compared with the
overall population. The median baseline sNfL level was 6.77 pg/
ml in the low and 15.29 pg/ml in the high sNfL category. As
expected, patients with high sNfL compared to those with low
sNfL levels at baseline showed higher baseline T2 lesion volume
(12.3 vs. 5.9 cm3), higher mean number of Gd+ T1 lesions (2.6 vs.
0.4), and a lower probability of being free of Gd+ T1 lesions (38%
vs. 75%).

3.2 Prognostic Value of sNfL
3.2.1 All Patients
3.2.1.1 Disease Activity as Measured by MRI Lesions or
Clinical Relapses
The prognostic value of baseline sNfL for on-study disease
activity was assessed based on MRI lesion formation (number
of neT2 lesions) and clinical relapses (ARR). Within each
treatment arm, patients with high sNfL levels at baseline
showed higher on-study accumulation of neT2 lesions per
year; neT2 lesions were 2.4 times in the ofatumumab group
(143% increase, p<0.001) and 1.75 times higher (75% increase,
p<0.001) in the teriﬂunomide group compared to those with low
sNfL levels at baseline (Figure 1A). High versus low sNfL at
baseline was prognostic of increased neT2 lesions both at year 1
(relative increase: ofatumumab, 157.5% and teriﬂunomide,
68.6%, both p<0.001; Figure 1B) and year 2 (relative increase:
ofatumumab, 64.5%, p=0.124 and teriﬂunomide, 45.6%, p=0.003;
Figure 1C). Even in the subgroup of patients free of Gd+ T1
lesions at baseline, i.e., those who would appear free of disease
activity based on the radiological assessment, high compared
with low baseline sNfL was still prognostic of signiﬁcantly higher
rate of annualized T2 lesion formation in both ofatumumab and
teriﬂunomide groups (Supplementary Figures 1A, B).
In these active-controlled clinical trials, sNfL at baseline was
not prognostic for on-study ARR, and relapse rates were not
statistically different between high and low sNfL groups (relative
reduction: ofatumumab, 27.0%, p=0.075; teriﬂunomide, 6.6%,
p=0.614; Figure 1D). However, ARR was not high in either
treatment group: pooled across the two trials, the ARR was 0.11
in the ofatumumab arm and 0.24 in the teriﬂunomide arm,
which corresponds to one clinical relapse within 9 years in
ofatumumab treated patients and one clinical relapse within 4
years in the teriﬂunomide arm.

3.2.2 Subgroup of Recently Diagnosed and
Treatment-Naive Patients
3.2.2.1 Risk of Future Demyelinating Events as Measured
by the Number of T2 Lesion Formation and Relapses
To assess the prognostic value of sNfL in patients who were
recently diagnosed and treatment naive, a subgroup analysis was
conducted. Patients with high compared with low sNfL levels at
baseline developed more neT2 lesions per year during the study
(relative increase: ofatumumab, 102.8%, p<0.001; teriﬂunomide,
98.4%, p<0.001; Figure 4A). However, the ARR was not
statistically different between the groups and was low in both
the arms, i.e., ARR ≤0.15, which corresponds to <1 relapse for
every 6 years of patient exposure (Figure 4B).
Recently diagnosed, treatment-naive patients with high
(compared to low) baseline sNfL levels experienced signiﬁcantly
more whole brain volume loss per year (relative difference:
ofatumumab, 131.8%, p=0.007; teriﬂunomide, 146.6%, p<0.001;
Figure 4C). Similar to the results in all RMS patients, newly
diagnosed, treatment-naive patients with high sNfL (compared to
low) levels at baseline lost more thalamus volume in the
teriﬂunomide group (relative difference: 149.6%, p=0.003), with
a similar but non-signiﬁcant trend also noted in the ofatumumab
group (relative difference: 174.5%, p=0.093; Figure 4D). In
addition, high baseline sNfL (vs. low) was prognostic of a higher
annual percentage volume change in WM in both treatment arms
(relative difference: ofatumumab, 182.1%, p=0.022; teriﬂunomide,
776.3%, p=0.002; Figure 4E) but did not show a signiﬁcantly
prognostic value for change in cGM volume, although the trend
was in the same direction (relative difference: ofatumumab,
143.8%, p=0.053; teriﬂunomide, 25.4%, p=0.408; Figure 4F).
Similar to overall population, the differences in the time to ﬁrst
3mCDW and 6mCDW were not statistically signiﬁcant between
high and low sNfL groups (data not shown) but demonstrated a
consistent trend.

3.2.1.2 Disease Worsening as Measured by Brain Volume
Change and Disability Outcomes
Within each treatment arm, patients with high sNfL levels at
baseline lost signiﬁcantly more whole brain volume per year
(slope between year 1 and 2) than those with low sNfL levels
(relative difference: ofatumumab, 37.0%, p=0.044; teriﬂunomide,
50.3%, p=0.002; Figure 2A). For the subgroup of patients with
and without Gd+ T1 lesions at baseline, high compared with low
baseline sNfL was associated with statistically signiﬁcantly higher
brain volume loss in the teriﬂunomide group, with a similar but
non-signiﬁcant trend also noted in the ofatumumab group
(Supplementary Figures 2A, B).
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FIGURE 1 | Prognostic value of baseline sNfL [high (red), ≥9.3 pg/ml; low (green), <9.3 pg/ml] on measures of disease activity in the overall study population:
annualized rate of neT2 lesions per year by baseline sNfL category in the interval (A) M0–M24, (B) M0–M12, and (C) M12–M24; (D) ARR M0–M24. Comparisons are
between high vs. low sNfL categories. 1Adjusted annualized mean rate of neT2 lesions. The number of neT2 lesions (compared to baseline or month 12) was
analyzed in a negative binomial model with adjustments for treatment, baseline sNfL category, region and study as factors, and age and baseline volume of T2
lesions as continuous covariates, and treatment by baseline sNfL category interaction. The natural log of the time from the baseline scan (in years) was used as the
offset. 2Indicates statistical signiﬁcance (two-sided) at the 0.05 level. 3The ARR was analyzed in a negative binomial regression model with log-link to the number of
relapses adjusted for treatment, baseline sNfL category, region and study as factors, number of relapses in previous year, baseline EDSS, baseline number of Gd+T1
lesions, and the patient’s age at baseline as covariates and treatment by baseline sNfL category interaction. The natural log of the time in study was used as offset to
annualize the relapse rate. ARR, annualized relapse rate; CI, conﬁdence interval; Gd+ gadolinium-enhancing; n, total number of relapses included in the analysis;
neT2, new or enlarging T2 lesions; sNfL, serum neuroﬁlament light; Y, number of patient-years in study.

r=−0.379; teriﬂunomide, r=−0.399, both p<0.0001) and 2 years
(−0.473; −0.460, both p<0.0001; Table 2; Figures 3C, D).

3.2.2.2 Correlations Between sNfL and Regional Brain
Volume Change
Similar to the results in the overall study population, of all the
brain compartments analyzed, relative changes in volume were
most pronounced in the thalamus. Baseline sNfL correlated with
the percentage change from baseline to month 12 and month 24 in
whole brain volume, WM volume, and thalamic volume, and, to a
lesser degree, with cGM volume change. The strongest association
of sNfL was with thalamic volume loss, both over 1 (ofatumumab,
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3.2.3 Treatment Effect of Ofatumumab by Baseline
NfL Category
Ofatumumab signiﬁcantly reduced T2 lesion formation
compared with teriﬂunomide regardless of baseline sNfL with
relative reductions of 82% and 87% in high and low sNfL groups,
respectively (Figure 5A). ARR was signiﬁcantly lower in the
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FIGURE 2 | Prognostic value of baseline sNfL [high (red), ≥9.3 pg/ml; low (green), <9.3 pg/ml] on brain volume change and disability worsening in the overall study
population*. Annual rate of brain volume change in (A) whole brain, (B) thalamus, (C) hemispheric white matter, and (D) cGM per year; time to disability worsening
(E) 3mCDW and (F) 6mCDW by NfL baseline category. Comparisons are between high vs. low sNfL categories. 1Adjusted annual rate of brain volume change as
estimated in from the random coefﬁcient model with study ﬁt to the post-baseline assessments measured at M12, M24, and end-of-study, treatment as ﬁxed effects
(factors), and time as continuous covariates and treatment by time interaction for the overall analysis, with additional co-factors of subgroup, treatment by subgroup,
treatment by time by subgroup interactions for the subgroup analysis. Random terms for slopes and intercept are included. 2Indicates statistical signiﬁcance (twosided) at the 0.05 level. Obtained from a random coefﬁcients model. 3Cox regression adjusted study as stratum, treatment, region, and sNfL baseline high–low
subgroup as factors and baseline EDSS as a continuous covariate along with treatment-by-sNfL baseline high–low subgroup interaction. *Descriptive analysis; the
study was not powered to analyze prognostic effects of sNfL on disability outcomes. 3m, 3month; 6m, 6month; ARR, annualized relapse rate; CDW, conﬁrmed
disability worsening; cGM, cortical gray matter; CI, conﬁdence interval; EDSS, Expanded Disability Status Scale Score; Gd+, gadolinium-enhancing; LS, least square;
M, month; sNfL, serum neuroﬁlament light; WM, white matter.

consistent for reduction in thalamic volume loss with relative
reduction of 40.6% (−0.56 vs. −0.94, p=0.003) (Figure 5D) but
not statistically signiﬁcant for WM or cGM volume loss. Greater
effects of ofatumumab versus teriﬂunomide on reducing
3mCDW and 6mCDW risk were noted irrespective of baseline
sNfL levels, corresponding to 34% and higher risk reduction in
patients with high sNfL and low sNfL (Figures 5E, F).

ofatumumab compared with teriﬂunomide arm (both p<0.001),
corresponding to a relative reduction of 60% and 48% in the high
and low sNfL groups, respectively (Figure 5B). In patients with
high sNfL who were treated with ofatumumab, the rate of brain
volume loss (between year 1 and 2) was lower than those treated
with teriﬂunomide resulting in a relative reduction of 24.5%
(−0.32 vs. −0.43, p=0.019) (Figure 5C). The treatment effect was
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TABLE 2 | Pearson correlation coefﬁcient between log-transformed baseline sNfL and percentage volume change in different brain compartments at months 12 and 24
from baseline in the overall study population and subgroup of recently diagnosed and treatment-naive patients.
Compartment

Baseline to month 12
Whole brain
Thalamus
Hemispheric white matter
Cortical gray matter
Baseline to month 24
Whole brain
Thalamus
Hemispheric white matter
Cortical gray matter

Treatment

All patients

Recently diagnosed, treatment-naive patients

N

Correlation

95% CI

p-value

N

Correlation

95% CI

p-value

Ofatumumab 20 mg
Teriﬂunomide 14 mg
Ofatumumab 20 mg
Teriﬂunomide 14 mg
Ofatumumab 20 mg
Teriﬂunomide 14 mg
Ofatumumab 20 mg
Teriﬂunomide 14 mg

795
760
785
758
794
760
795
760

−0.200
−0.203
−0.374
−0.308
−0.230
−0.207
−0.026
−0.070

(−0.266, −0.132)
(−0.270, −0.134)
(−0.432, −0.312)
(−0.371, −0.242)
(−0.295, −0.163)
(−0.275, −0.138)
(−0.095, 0.044)
(−0.141, 0.001)

<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.4679
0.0523

256
272
255
265
256
272
257
271

−0.199
−0.172
−0.379
−0.399
−0.234
−0.225
−0.006
0.042

(−0.314, −0.078)
(−0.285, −0.054)
(−0.480, −0.269)
(−0.495, −0.292)
(−0.347, −0.115)
(−0.335, −0.109)
(−0.128, 0.117)
(−0.078, 0.160)

0.0013
0.0044
<0.0001
<0.0001
0.0001
0.0002
0.9289
0.4958

Ofatumumab 20 mg
Teriﬂunomide 14 mg
Ofatumumab 20 mg
Teriﬂunomide 14 mg
Ofatumumab 20 mg
Teriﬂunomide 14mg
Ofatumumab 20 mg
Teriﬂunomide 14mg

624
597
614
588
623
597
624
598

−0.282
−0.269
−0.416
−0.367
−0.292
−0.286
−0.080
−0.068

(−0.353, −0.209)
(−0.342, −0.193)
(−0.479, −0.348)
(−0.435, −0.295)
(−0.362, −0.218)
(−0.358, −0.210)
(−0.157, −0.001)
(−0.147, 0.012)

<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.0466
0.0965

213
203
208
195
213
202
214
203

−0.384
−0.308
−0.473
−0.460
−0.409
−0.311
−0.095
−0.075

(−0.493, −0.263)
(−0.427, −0.177)
(−0.572, −0.360)
(−0.564, −0.342)
(−0.515, −0.290)
(−0.430, −0.181)
(−0.226, 0.040)
(−0.210, 0.063)

<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.1674
0.2883

N, number of patients included in the analysis. Negative correlation coefﬁcients signify the high sNfL values were correlated with negative brain volume values. Signiﬁcant correlation
coefﬁcients are presented in bold.
CI, conﬁdence interval; sNfL, serum neuroﬁlament light chain.

T1 lesions at baseline, and thus would be considered low risk
patients based on the clinical and radiological assessment, it was
shown that baseline sNfL could prognosticate the risk of future MS
disease activity and worsening as measured by lesion formation
and brain volume loss. This may be of relevance in the assessment
of newly diagnosed or early MS patients in whom a reliable risk
stratiﬁcation is difﬁcult in current practice. Two plausible
mechanisms could explain the observed additional value of NfL
over standard MRI in prognosticating future MS disease activity.
First, MS-related spinal cord injury may be reﬂected in increased
NfL levels, but it will not be invisible on a brain image. Second,
NfL can be elevated for longer than gadolinium-enhancing lesions
appearing visible on the radiological image, i.e., NfL may detect
past lesion activity that cannot be detected anymore by a standard
radiological assessment.
In our analysis, baseline sNfL correlated with whole brain and
regional atrophy, with the strongest correlation with thalamic
volume change. The thalamus is a small but particularly neuronrich structure; it is a relay station for many long distance afferent
and efferent white matter tracts and is affected early in MS (33). It
has been previously shown that thalamic atrophy was associated
with clinical disease progression (6, 7) and cognitive impairment
(34) in MS. In a cross-sectional study including patients with MS,
higher baseline sNfL levels were associated with lower baseline
deep gray matter volumes, including thalamus, caudate, and
hippocampus (35). More recent work, which focused on brain
network hubs, revealed that a high T2 lesion volume at baseline
was predictive of on-study cGM, deep GM, and thalamic volume
loss (7). In both ASCLEPIOS studies, reduction in thalamic
volume loss was slowed by ofatumumab compared with
teriﬂunomide (ASCLEPIOS I: ofatumumab vs. teriﬂunomide,
1.00% vs. 1.40%, p=0.002; ASCLEPIOS II: −1.07 vs. 1.31%,

4 DISCUSSION
This protocol-planned analysis from the two large phase 3
ASCLEPIOS I and II trials conﬁrms the prognostic value of
baseline sNfL levels for on-study lesion formation and brain
volume change in patients with RMS. The prognostic value of
baseline sNfL on MRI lesion formation and brain volume loss
over 1 to 2 years was consistently seen in both ofatumumab- and
teriﬂunomide-treated patients, suggesting that the prognostic
effect of sNfL is not limited to a speciﬁc treatment. Compared
to patients with low sNfL levels in the same treatment group,
patients with high sNfL levels at baseline developed 50%–150%
more T2 lesions on-study, which is a relevant information to
treating physicians, as it may inﬂuence long-term outcomes and,
in combination with other assessments, guide treatment
decisions. The prognostic value of baseline sNfL for lesion
formation persisted in the second year of treatment in the
teriﬂunomide arm, indicating that baseline sNfL has a
clinically meaningful prognostic capacity beyond current
assessments. Patients who were identiﬁed as having high NfL
at baseline who were then randomized to teriﬂunomide had on
average >5 new or enlarging T2 lesions in the ﬁrst year of
treatment, and lesion formation persisted to be high (>4 new
or enlarging T2 lesions) in the second year of treatment. In
contrast, high baseline NfL patients who were randomized to
ofatumumab arm had 1.4 lesions in the ﬁrst year of treatment but
close to complete abrogation of lesion formation in the second
year of treatment (0.09 lesions per year), showing that new
demyelinating events could largely be prevented even in “high
NfL” patients with highly efﬁcacious treatment.
NfL assessments had added value over standard MRI
assessments in our study. In patients who appeared free of Gd+
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A
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FIGURE 3 | Correlation between baseline sNfL concentrations and on-study whole and regional brain volume change as illustrated in scatter plots over the speciﬁed
time period in either the overall population (A: baseline to M12; B: baseline to M24), or in the subgroup of recently diagnosed, treatment-naive patients (C: baseline
to M12; D: baseline to M24). Random coefﬁcients model adjusted for study, treatment, region, and baseline sNfL category as ﬁxed effects factors; time, baseline
number of Gd+ T1 lesions, baseline T2 volume, and normalized brain volume (whole or regional) at baseline as continuous covariates; and treatment-by-time-bybaseline sNfL category interaction and the three corresponding two-way interactions. Gd+, gadolinium-enhancing; M, month; NfL, neuroﬁlament light chain.

p=0.044). These ﬁndings are in line with the disability outcomes
of these phase 3 studies but different from results for whole brain
volume change alone, which was not signiﬁcantly different
between treatment arms (30). Although this study was not
powered to demonstrate a prognostic effect of sNfL on
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disability outcomes, as noted by the protocol, trends were
directionally consistent with the results on whole brain and
thalamus changes. It is of note that in these active controlled
studies, approximately 90% of the ofatumumab-treated patients
had no 3mCDW over up to 2.3 years, and in the teriﬂunomide
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FIGURE 4 | Prognostic value of baseline sNfL category [high (red), ≥9.3 pg/ml; low (green), <9.3 pg/ml) on measures of MS disease activity and worsening, in the
subgroup of recently diagnosed, treatment-naive patients. (A) neT2 lesions per year, (B) annualized relapse rate. Annual rate of brain volume change in the (C) whole
brain, (D) thalamic volume, (E) hemispheric WM, (F) cortical gray matter. Comparisons are between high vs. low sNfL categories. 1The number of neT2 lesions
(compared to baseline or month 12) was analyzed in a negative binomial model with adjustments for treatment, baseline sNfL category, region and study as factors,
and age, baseline volume of T2 lesions as continuous covariates, and treatment by baseline sNfL category interaction. The natural log of the time from the baseline
scan (in years) was used as the offset. 2Indicates statistical signiﬁcance (two-sided) at the 0.05 level. 3Negative binomial regression model with log-link to the number
of relapses adjusted for treatment, baseline sNfL category, region and study as factors, number of relapses in previous year, baseline EDSS, baseline number of Gd
+T1 lesions, and the patient’s age at baseline as covariates and treatment by baseline sNfL category interaction. The natural log of the time in study was used as
offset to annualize the relapse rate. 4Annual rate of brain volume change obtained from a random coefﬁcients model with study, treatment as ﬁxed effects (factors),
and time as continuous covariates and treatment by time interaction for the overall analysis, with additional co-factors of subgroup, treatment by subgroup, and
treatment by time by subgroup interactions for the subgroup analysis. Random terms for slopes and intercept are included. ARR, annualized relapse rate; BVL, brain
volume loss; CI, conﬁdence interval; cGM, cortical gray matter; EDSS, Expanded Disability Status Scale score; Gd+, gadolinium-enhancing; neT2, new or enlarging
T2 lesions; LS, least square; sNfL, serum neuroﬁlament light; WM, white matter.

prognostic test, if standardized, could be a helpful tool in
assessing the patient’s risk of future disease activity and
worsening and could complement the clinical and radiological
assessments. In this regard, periodic assessments of sNfL may
help in assessing a patient’s risk of further subclinical disease
activity and brain tissue loss and “silent progression” in RRMS

arm, 85% of the patients remained free of 3mCDW, making it
challenging to analyze disability outcomes in subgroups of
patients. In clinical practice, one of the greatest challenges is
the difﬁculty to prognosticate future disease trajectories and
optimize treatment decisions at presentation because of the
extreme variability of individual disease courses (14). A
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FIGURE 5 | Treatment effect of ofatumumab compared with teriﬂunomide in the overall patient population, by baseline sNfL category, on measures of MS disease activity,
namely, (A) neT2 lesions and (B) ARR, and disease worsening, namely, (C) whole brain volume change and (D) thalamic volume change time to (E) 3mCDW and (F)
6mCDW. 1Adjusted annualized mean rate of neT2 lesions. The number of neT2 lesions (compared to baseline or month 12) was analyzed in a negative binomial model with
adjustments for treatment, baseline sNfL category, region and study as factors, and age, baseline volume of T2 lesions as continuous covariates, and treatment by baseline
sNfL category interaction. The natural log of the time from the baseline scan (in years) was used as the offset. 2The ARR was analyzed in a negative binomial regression
model with log-link to the number of relapses adjusted for treatment, baseline sNfL category, region and study as factors, number of relapses in previous year, baseline
EDSS, baseline number of Gd+T1 lesions, and the patient’s age at baseline as covariates and treatment by baseline sNfL category interaction. The natural log of the time in
study was used as offset to annualize the relapse rate. 3Adjusted annual rate of brain volume change as estimated in from the random coefﬁcient model with study ﬁt to the
post-baseline assessments measured at M12, M24, and end-of-study, treatment as ﬁxed effects (factors), and time as continuous covariates and treatment by time
interaction for the overall analysis, with additional co-factors of subgroup, treatment by subgroup, and treatment by time by subgroup interactions for the subgroup analysis.
Random terms for slopes and intercept are included. 4Cox regression adjusted study as stratum, treatment, region, and sNfL baseline high–low subgroup as factors and
baseline EDSS as a continuous covariate along with treatment-by-sNfL baseline high-low subgroup interaction. ARR, annualized relapse rate; BVL, brain volume loss;
3mCDW, 3-month conﬁrmed disability worsening; MRI, magnetic resonance imaging; neT2, new or enlarging T2 lesions; n.s., non-signiﬁcant; sNfL, serum neuroﬁlament
light chain.
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higher vs. lower than median sNfL. Recent work on sNfL
threshold optimization suggests that the risk of disease activity
and worsening increases gradually with increasing sNfL levels
and that there is a relationship of increasing sNfL concentrations
with older age, which becomes more prominent above the age of
50 years (41). It is likely that the threshold could be optimized
further in future analyses and with a speciﬁc target endpoint in
mind. Any such cut-point optimization should be done in the
context of the intended use of an in vitro diagnostic device
development to ensure the utility of such a tool in clinical
practice. Our study demonstrated prognostic value of sNfL for
on-study disease activity and worsening for ofatumumab and
teriﬂunomide in the independent Phase 3 ASCLEPIOS I and
II trials.
In conclusion, baseline sNfL levels are prognostic for on-study
lesion formation and brain volume loss, in all RMS patients but
speciﬁcally also in early treatment-naive patients. Irrespective of
the baseline sNfL levels, ofatumumab consistently reduced sNfL
concentrations relative to treatment with teriﬂunomide. The
relations shown between baseline sNfL and both T2 lesion
occurrence and brain volume loss during the study support that
sNfL levels are a prognostic indicator of tissue damage. This study
also supports the potential prognostic value of both sNfL and T2
lesions as predictors of higher probability of clinical progression in
patients with MS.

patients (36). Especially early in the disease, much of the disease
activity may be asymptomatic, and tissue damage is more
difﬁcult to recognize because of the high existing
compensation and reorganization capacity (37). However, the
radiological disease burden increases with each demyelinating
event, and therefore, looking beyond the surface with a sNfL test
may be particularly important. Our study conceptually conﬁrms
that sNfL has prognostic value for on-study lesion formation and
brain volume loss also in the subgroup of recently diagnosed
(within 3 years), treatment-naive patients. A high radiological
disease burden (as measured by the T2 lesion volume) is a key
factor that can predict further brain tissue loss (4), neuronal
injury and putatively loss (3), and unfavorable long-term
outcomes in patients (38). The prognostic value of baseline
sNfL for lesion formation, brain volume loss, and directionally
consistent results on disability worsening supports the clinical
meaningfulness of the prognostic value of sNfL for future disease
activity and worsening. In the active controlled ASCLEPIOS I
and II studies, we could not conﬁrm a prognostic effect on the
ARR, which was low in both treatment arms (one relapse for
every 9 years on ofatumumab versus one relapse for every 4 years
in the teriﬂunomide arm). However, lesion formation and
clinical relapses are both expressions of the same underlying
pathophysiology, and it seems plausible that without active
treatment, the prognostic effect on inﬂammatory demyelinating
disease activity as demonstrated on lesion formation would have
translated to a corresponding result in clinical relapses, as this
was shown in previous studies with higher levels of disease
activity (3, 9, 26, 29, 39, 40).
Irrespective of the sNfL level at baseline, in both ASCLEPIOS
I and II studies treatment with ofatumumab signiﬁcantly reduced
sNfL concentrations relative to treatment with teriﬂunomide by
8.7% at the ﬁrst assessment at month 3, 26.5% at month 12, and
23.8% at month 24 (p<0.001 for all time points) (30). A
continuous reduction in sNfL levels as seen with ofatumumab
treatment, corresponding to a reduction in irreversible neuronal
loss, is likely a meaningful patient outcome.
As strengths of the present study, all analyses (including NfL
thresholds, subgroup deﬁnitions, and statistical methodology)
were pre-speciﬁed in the study protocol and the corresponding
statistical analysis plan of ASCLEPIOS I and II, reducing the
chances of reporting bias. For brevity, the results for the
combined ASCLEPIOS I and II Phase 3 studies were reported.
However, similar analyses were conducted in each study
separately. Results of the two studies were independent as
patients, centers, and investigators could only participate in
one of the studies. Results of these two large studies in a total
of 1,882 patients were highly consistent, individually conﬁrming
the prognostic value of baseline sNfL for on-study lesion
formation and brain volume loss in both the ofatumumab and
teriﬂunomide arms.
As a limitation and based on the pre-planned nature of the
analysis, patients were stratiﬁed into “high” or “low” sNfL value
at baseline with the intention to divide a typical RMS population
(as deﬁned by the inclusion and exclusion criteria of the
ASCLEPIOS I and II studies) into groups of equal size with

Frontiers in Immunology | www.frontiersin.org

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.

ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by relevant institutional review board or ethics
committee at each trial site. The patients/participants provided
their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS
TZ, DA, EA, AC, SH, LK, JK, HK, KR, MM, and WS contributed
to study concept, data interpretation, and manuscript
development. RW, BL, and PK contributed to data analysis
and interpretation and manuscript development. DH
contributed to study concept, data analysis and interpretation,
and manuscript development. All authors contributed to the
article and approved the submitted version.

ACKNOWLEDGMENTS
The authors thank the participants for their involvement in and
commitment to the ASCLEPIOS trials and the clinical study

12

March 2022 | Volume 13 | Article 852563

Ziemssen et al.

Prognostic Value of Serum Neuroﬁlament

team for the conduct of the study. The authors are grateful to
Vimal Kumar Muthyala and Anuja Shah (Novartis Healthcare
Pvt. Ltd., Hyderabad, India) for providing medical writing
support. These services were sponsored by Novartis Pharma AG.

category, region and study as factors, and age, baseline volume of T2 lesions as
continuous covariates, and treatment by baseline sNfL category interaction. The
natural log of the time from the baseline scan (in years) was used as the offset.
2
Indicates statistical signiﬁcance (2-sided) at the 0.05 level. CI, conﬁdence interval;
Gd+, gadolinium-enhancing; neT2, new or enlarging T2 lesions; sNfL, serum
neuroﬁlament light.

SUPPLEMENTARY MATERIAL

Supplementary Figure 2 | Prognostic value of baseline sNfL category (high [red]:
≥9.3 pg/ml, low [green]: <9.3 pg/ml) on the annual rate of whole brain volume
change1 in the subgroup of patients (A) with Gd+ T1 lesions and (B) without Gd+
T1 lesions.Comparisons are between high vs low sNfL categories. 1Adjusted mean
annual rate of percent change from baseline obtained from a random coefﬁcients
model with study, treatment, NfL high-low subgroup, and region as factors, time,
number of Gd+ T1 lesions at baseline, baseline T2 volume, and normalized volume
of the analyzed compartment at baseline as continuous covariate, and treatmentby-time-by-subgroup interaction as well as the 3 corresponding 2-way interactions.
Random terms for slopes and intercept are included. 2Indicates statistical
signiﬁcance (2-sided) at the 0.05 level. BVL, brain volume loss; CI, conﬁdence
interval; cGM, cortical gray matter; Gd+, gadolinium-enhancing; LS, least square;
sNfL, serum neuroﬁlament light; WM, white matter.

The Supplementary Material for this article can be found online
at: https://www.frontiersin.org/articles/10.3389/ﬁmmu.2022.
852563/full#supplementary-material
Supplementary Figure 1 | Prognostic value of baseline sNfL category (high [red]:
≥9.3 pg/ml, low [green]: <9.3 pg/ml) on the annualized rate of neT2 lesion formation
per year in patients (A) with Gd+ T1 lesions and (B) without Gd+ T1 lesions.
Comparisons are between high vs low sNfL categories. 1Adjusted annualized mean
rate of neT2 lesions. The number of neT2 lesions (compared to baseline) was
analyzed in a negative binomial model with adjustments for treatment, baseline sNfL
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